Amgen says its Ozempic competitor helped patients lose 20% of their weight. Wall Street isn't impressed
Iulian Moșneagu
In This Story AMGN -7.49% NVO +1.39% LLY +5.33% MS -1.97% PFE -1.68% Amgen ( AMGN -7.49% ) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and potential Ozempic competitor MariTide, however, Wall Street wasn’t very impressed. Suggested Reading Spirits Airlines filed late earnings — and they show how bad things got before bankruptcy Donald Trump's best and worst cabinet picks, according to an analyst Best Buy says Trump's tariffs could
din zilele anterioare